tocilizumab
AssetAlso CT-P47 AI, MRA, ATLIZUMAB, BAT-1806
Blocks interleukin-6 receptor signaling to reduce inflammation.
- Stage
- Approved
- Modality
- Antibody
- Target
- Inflammation
- 13
- Indications
- 359
- Trials
- 2
- Developers
Indications
13Arthritis, Juvenile
Approved, ema.europa.eu, 11 Oct 2026
Arthritis, Juvenile Rheumatoid
Approved, ema.europa.eu, 11 Oct 2026
Arthritis, Rheumatoid
Approved, accessdata.fda.gov, 11 Oct 2026
10 more
In the full profile
- Targets and what it contains2
- Owner and partners2
- Trials359
- Evidence for its targets3
- Competitors12
- Aging relevance1
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.